Argenx to Buy Forte Biosciences for $2.2 Billion
Dow Jones2026/07/27 05:21By Adria Calatayud
Argenx said it reached an agreement to buy Forte Biosciences for $2.2 billion, moving to strengthen its immunology pipeline.
European pharmaceutical company Argenx is acquiring Nasdaq-listed Forte for $77 a share in cash, the companies said Monday. The price represents a 41% premium to Forte's closing price on Friday.
Argenx said the deal allows it to add to its pipeline Forte's experimental drug FB102, for which it sees potential to address diseases with high unmet need that have lacked new treatments.
Forte recently reported results of an early-stage clinical trial for the drug that showed a significant treatment benefit in skin condition vitiligo, building on data released last year for another study in celiac disease. Argenx said the drug has potential to address multiple autoimmune diseases.
The boards of both companies have approved the transaction, which is expected to close in the third quarter subject to customary closing conditions, they said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 27, 2026 01:21 ET (05:21 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave’s $132.5 billion backlog raises pressure on Nebius ahead of Q3 results
New Statements and Predictions from an Executive Who Expects Bitcoin to Reach $1.6 Million
PNC Bank Launches USDC Payment Acceptance for Corporate Clients
British Pound tumbles below 1.33 post hot US CPI, Fed hawkish rhetoric
Crypto prices
More
